ProPhase Labs, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ProPhase Labs, Inc. (PRPH) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $261.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-31.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2021-03-31
- ProPhase Labs, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was $261.00K.
- ProPhase Labs, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2019 was -$522.00K.
- ProPhase Labs, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2018 was -$105.00K.
- ProPhase Labs, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2017 was -$16.09M, a 1706.19% decline from fiscal 2016.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2020-12-31 | $261.00K 10-K · filed 2021-03-31 | |
| 2019-12-31 | -$522.00K 10-K · filed 2021-03-31 | |
| 2018-12-31 | -$105.00K 10-K · filed 2020-03-26 | |
| 2017-12-31 | -$16.09M 10-K · filed 2019-03-26 | -$17.49M 10-K · filed 2018-03-28 |
| 2016-12-31 | $1.00M 10-K/A · filed 2018-08-20 | -$1.00M 10-K · filed 2017-02-24 |
| 2015-12-31 | $1.48M 10-K/A · filed 2018-08-20 | -$1.48M 10-K · filed 2016-03-29 |
| 2014-12-31 | -$2.54M 10-K · filed 2017-02-24 | |
| 2013-12-31 | $217.00K 10-K · filed 2016-03-29 | |
| 2012-12-31 | $759.00K 10-K · filed 2015-03-27 | |
| 2011-12-31 | -$898.00K 10-K · filed 2014-03-27 | |
| 2010-12-31 | $53.00K 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |